Dr. Oleg Krijanovski is an internist in Ann Arbor, Michigan and is affiliated with Alta Bates Summit Medical Center. He received his medical degree from Russian State Medical University and has been in practice for 29 years.
Education & Medical Training
University of Michigan Hospitals and Health Centers
Residency, Anatomic and Clinical Pathology, 1999–2001
University of Michigan Hospitals and Health Centers
Residency, Internal Medicine, 2001–2003
University of Michigan Hospitals and Health Centers
Fellowship, Hematology/Oncology, 2003–2006
Russian State Medical University
Class of 1985
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
KrijanO@sutterhealth.org
Related Clinical Trials
Bone Marrow Transplant Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Investigators: Deepti Behl MD, Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Chronic Lymphocytic Leukemia
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Follicular Lymphoma
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With R
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
MajesTEC-9
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Particip
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Neoadjuvant (EPCORE DLBCL-2)
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydr
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting